PROM1 and ovarian carcinoma: Consistent with the latter, (Yifeng et al., 2018) used meta-analysis to provide more significant evidence and concluded that CD133 expression along with CD44 is indicative of advanced FIGO level, degree of differentiation, and chemotherapy resistance in ovarian cancer cells.